![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Resistance Analysis of Long-Acting Lenacapavir in Highly Treatment-Experienced People With HIV After 52 Weeks of Treatment
|
|
|
AIDS 2022 July 29 - Aug 1 Montreal
Nicolas Margot, Laurie VanderVeen, Vidula Naik, Hadas Dvory-Sobol, Martin S. Rhee, Christian Callebaut - Gilead Sciences, Inc., Foster City, California, USA
![0803221copy](../images/080322/080322-4/0803221copy.gif)
![0803222copy](../images/080322/080322-4/0803222copy.gif)
![0803223copy](../images/080322/080322-4/0803223copy.gif)
![0803224copy](../images/080322/080322-4/0803224copy.gif)
![0803225copy](../images/080322/080322-4/0803225copy.gif)
![0803226copy](../images/080322/080322-4/0803226copy.gif)
![0803227copy](../images/080322/080322-4/0803227copy.gif)
![0803228copy](../images/080322/080322-4/0803228copy.gif)
![0803229opy](../images/080322/080322-4/0803229opy.gif)
![08032210copy](../images/080322/080322-4/08032210copy.gif)
![08032211copy](../images/080322/080322-4/08032211copy.gif)
![08032212copy](../images/080322/080322-4/08032212copy.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|